[
    [
        {
            "time": "2019",
            "original_text": "昭衍新药港股上市首日破发 2019年国内非临床DSA市占率第一 连续下跌",
            "features": {
                "keywords": [
                    "昭衍新药",
                    "港股",
                    "上市",
                    "破发",
                    "非临床DSA",
                    "市占率",
                    "连续下跌"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "昭衍新药港股上市首日破发 2019年国内非临床DSA市占率第一 连续下跌",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "广生堂(300436.SZ)确定泰格医药为乙肝创新药“GST-HG141”Ib期临床试验CRO",
            "features": {
                "keywords": [
                    "广生堂",
                    "泰格医药",
                    "乙肝",
                    "创新药",
                    "GST-HG141",
                    "Ib期临床试验",
                    "CRO"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "广生堂(300436.SZ)确定泰格医药为乙肝创新药“GST-HG141”Ib期临床试验CRO",
                "Correlation": 9,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "广生堂(300436.SZ)：GST-HG141已完成Ia期临床试验暨确定泰格医药为Ib期临床试验CRO",
            "features": {
                "keywords": [
                    "广生堂",
                    "GST-HG141",
                    "Ia期临床试验",
                    "泰格医药",
                    "Ib期临床试验",
                    "CRO"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "广生堂(300436.SZ)：GST-HG141已完成Ia期临床试验暨确定泰格医药为Ib期临床试验CRO",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "大摩增持泰格医药(03347)约29.69万股，每股作价180.69港元",
            "features": {
                "keywords": [
                    "大摩",
                    "增持",
                    "泰格医药",
                    "29.69万股",
                    "180.69港元"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "大摩增持泰格医药(03347)约29.69万股，每股作价180.69港元",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "【权益变动】泰格医药(03347-HK)获摩根士丹利增持约29.69万股",
            "features": {
                "keywords": [
                    "权益变动",
                    "泰格医药",
                    "摩根士丹利",
                    "增持",
                    "29.69万股"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "【权益变动】泰格医药(03347-HK)获摩根士丹利增持约29.69万股",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "0219",
            "original_text": "晨报0219 | 医药春季策略、新式茶饮行业专题、盘江股份（600395）",
            "features": {
                "keywords": [
                    "医药春季策略",
                    "新式茶饮",
                    "盘江股份"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "消费"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "晨报0219 | 医药春季策略、新式茶饮行业专题、盘江股份（600395）",
                "Correlation": 3,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 4,
                "Entity_Density": 4,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]